Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Seagen Inc. (SGEN) said Thursday that the U.S. Food and Drug Administration has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that ha
:max_bytes(150000):strip_icc():format(jpeg)/retireeonbench-2b00ae998d0d4d719bad1ac03855dd7a-77bcd0958cc54ea48284519c49430cd3.jpg "What Are the 2024 Roth 401(k) Contribution Limits?")